NCI seeks to develop clinical trial of MCED tests

NCI has issued a Request for Information seeking input from developers of multi-cancer early detection liquid biopsy tests, with the goal of launching an NCI-sponsored randomized controlled screening clinical trial of these tools.

“Multi-cancer early detection tests are being developed by many laboratories, and the potential for this technology to benefit the cancer screening process is exciting, but, there is a lot that we do not know about either the benefits or harms of screening for cancer with this type of test,” Lori Minasian, deputy director of the NCI Division of Cancer Prevention, said to The Cancer Letter.

“An MCED assay is just the first step in the process of being diagnosed with cancer, and each assay works differently. We are looking for input from a variety of sources on studies to assess these assays more fully,” Minasian said.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

Byline

Alice Tracey

Reporter

DOWNLOAD THE PDF

Table of Contents

YOU MAY BE INTERESTED IN

Podcast

The Directors: Candace Johnson and Jonathan Friedberg on living through uncertainty at NCI, payment woes
Directors of two neighboring cancer centers in Upstate New York will face challenges, but “we’ll get through it”

Candace S. Johnson leads America’s oldest cancer research center and Jonathan W. Friedberg leads the newest NCI-designated center. Their catchment areas are contiguous, their faculty and staff members collaborate often, and together their institutions embody the culture of NCI-designated cancer centers.

In first NCAB meeting since Trump’s inauguration, Lowy reflects on funding choices in lean times
“In the NCI director’s office, we have a photograph of a stone bridge, and it asks the question, which stone holds up the bridge? And the answer is all of them.”

In the first meeting of the National Cancer Advisory Board since the inauguration of President Donald Trump, NCI Principal Deputy Director Douglas R. Lowy addressed many of the burning questions the oncology field has for the institute. On indirect costs: NCI will continue to use previously negotiated and approved indirect cost rates, with the exception...

George Sigounas named the first-ever chief science advisor at NCI

George Sigounas, an expert in bone marrow transplantation, was named to the newly created post of chief science advisor at NCI.

Success rates for RPGs at NCI would plummet from 13.4% to 8.3% if Trump’s FY2026 budget is enacted

Congressional Justifications displaying the details of the President Trump’s budget request for the fiscal year 2026 show that the success rates for Research Project Grants at NCI would plummet from 13.4% in FY2024 to 8.3% during the next fiscal year.

FDA booth stood empty at 2025 ASCO annual meeting

Booth 10025 became an unlikely crowd magnet at the exhibit hall at the annual meeting of the American Society of Clinical Oncology that ended earlier this week.

ALT GOV: The HHS “resistance” on social media

After a sequence of events that unfolded publicly on NCI’s Instagram feed May 28, RIFed and “retired” members of the NCI communications team took to the independent social media platform BlueSky, creating an alternative and anonymous social media presence.

June 06, 2025

Vol.51 No.22

By Claire Marie Porter

NCI seeks to develop clinical trial of MCED tests

YOU MAY BE INTERESTED IN

The Directors: Candace Johnson and Jonathan Friedberg on living through uncertainty at NCI, payment woes
Directors of two neighboring cancer centers in Upstate New York will face challenges, but “we’ll get through it”

In first NCAB meeting since Trump’s inauguration, Lowy reflects on funding choices in lean times
“In the NCI director’s office, we have a photograph of a stone bridge, and it asks the question, which stone holds up the bridge? And the answer is all of them.”

George Sigounas named the first-ever chief science advisor at NCI

Success rates for RPGs at NCI would plummet from 13.4% to 8.3% if Trump’s FY2026 budget is enacted

FDA booth stood empty at 2025 ASCO annual meeting

ALT GOV: The HHS “resistance” on social media

Renew today!

Subscriber content

Never miss an issue!

Login

NCI seeks to develop clinical trial of MCED tests

YOU MAY BE INTERESTED IN

The Directors: Candace Johnson and Jonathan Friedberg on living through uncertainty at NCI, payment woesDirectors of two neighboring cancer centers in Upstate New York will face challenges, but “we’ll get through it”

In first NCAB meeting since Trump’s inauguration, Lowy reflects on funding choices in lean times“In the NCI director’s office, we have a photograph of a stone bridge, and it asks the question, which stone holds up the bridge? And the answer is all of them.”

George Sigounas named the first-ever chief science advisor at NCI

Success rates for RPGs at NCI would plummet from 13.4% to 8.3% if Trump’s FY2026 budget is enacted

FDA booth stood empty at 2025 ASCO annual meeting

ALT GOV: The HHS “resistance” on social media

Never miss an issue!

Login

The Directors: Candace Johnson and Jonathan Friedberg on living through uncertainty at NCI, payment woes
Directors of two neighboring cancer centers in Upstate New York will face challenges, but “we’ll get through it”

In first NCAB meeting since Trump’s inauguration, Lowy reflects on funding choices in lean times
“In the NCI director’s office, we have a photograph of a stone bridge, and it asks the question, which stone holds up the bridge? And the answer is all of them.”